3 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 3 of 3 clinical reviews.
Evidence-based review of how tadalafil pharmacokinetics, dosing, and adverse-event rates differ in East Asian populations, including CYP3A4 metabolism data, Japanese regulatory decisions, and practical prescribing guidance.
How South Asian genetics, cardiovascular risk factors, and metabolic patterns affect tadalafil (Cialis) safety, dosing, and monitoring. Evidence-based guidance with pharmacogenomic context.
A guide to tadalafil dosing in South Asian patients, covering CYP3A4 and CYP2C9 variants, cardiovascular risk at lower BMI, drug interactions with metformin and statins, and evidence-based dose adjustment protocols.